

Health Canada releases draft pre-market guidance for machine learning medical devices

01 septembre 2023

On Aug. 30, 2023, Health Canada released its anticipated [draft guidance document on obtaining authorization for machine learning-enabled medical devices](#) (machine learning medical devices). This publication seeks to assist manufacturers of class II, III, and IV machine learning medical devices who are submitting applications for, or amendments to, a Medical Device License. The guidance document outlines Health Canada's expectations for demonstrating the machine learning medical devices' safety and effectiveness requirements required under s. 10 of the [Medical Device Regulations](#) (MDR), and introduces a proposed mechanism for manufacturers to obtain pre-authorization for planned changes to one of its existing machine learning medical devices.

Safety and effectiveness requirements

Medical devices that use machine learning technology to accomplish their intended medical purpose are called machine learning medical devices. Machine learning medical devices present challenges to regulators seeking to evaluate the device's safety and effectiveness because, by their very nature, machine learning medical devices are continually evolving.

The current regulatory scheme addresses safety and effectiveness requirements. Under section 10 of the MDR, the manufacturer of a medical device is required to "take reasonable measures" to identify the risks inherent in the device, reduce or eliminate risks where possible, and provide protection and information appropriate to those risks during the projected useful life of the device.

Key takeaways from the draft guidance:

- Manufacturers should clearly state in a cover letter for all Class II, III, and IV applications that their device uses machine learning. Manufacturers will also want to ensure that there is objective evidence that supports the safety and effectiveness of their machine learning medical device relevant to its intended use. The evidence should also include a description of how the manufacturer has implemented good machine learning practices that remain implemented throughout the machine learning medical device's product lifecycle. For a

summary of these GMLP, please our article on Health Canada's [Guiding Principles on Artificial intelligence and Machine Learning for Medical Devices](#).

- Manufacturers are encouraged to provide detailed description of the kinds of information Health Canada is seeking in machine learning medical device **applications relating to the device's intended use, indications for use, contraindications, clinical validation, device description, product labelling, risk management strategies, and data selection and management.**
- The guidance encourages manufactures to consider providing descriptions of the machine learning development, training, and tuning approaches, system performance testing, and post-market performance monitoring.
- **Health Canada's guidance has also introduced the concept of a Pre-determined Change Control Plan (PCCP) that manufacturers would submit as a standalone section in their MDL application. Through the PCCP, a manufacturer can seek pre-approval for otherwise significant changes in its machine learning medical device's design and performance that would otherwise require an MDL amendment application.**
- The PCCP is proposed to consist of three sections: change description, change protocol, and impact assessment. **The PCCP's change description section invites manufacturers to characterize the machine learning medical device's baseline design and performance and list anticipated or planned changes across the product's life cycle (whether by the manufacturer, a user, a patient, or by the device itself).** The change protocol section would require manufacturers to describe the set of policies and procedures that control how the planned or anticipated changes will be implemented and managed in a manner that ensures **the machine learning medical device's safety and effectiveness. Depending on the nature of the machine learning medical device and the planned/anticipated changes, the change protocol may need to include the manufacturer's plans for ongoing data/risk management, modification/update procedures, monitoring, and corrective actions.** Finally, the impact assessment section would require manufacturers to outline the potential influence and implications of the changes listed in its PCCP.

Finalization of the draft guidance and opportunity for industry feedback

Health Canada is soliciting feedback on its draft guidance from Class II to IV medical device manufacturers, regulatory representatives, and machine learning experts. For example, Health Canada has requested feedback whether it should add or remove any information that manufacturers would be required to provide in PCCP sections. The window to provide Health Canada with input closes Oct. 29, 2023, after which the guidance document will be finalized.

For any assistance with product regulatory related inquiries, please feel free to get in touch with the key contacts below.

Par

[Edona C. Vila, Benjamin Fuhrmann](#)

Services

[Droit de la santé, Droit des produits, Soins de santé et sciences de la vie](#)

BLG | Vos avocats au Canada

Borden Ladner Gervais S.E.N.C.R.L., S.R.L. (BLG) est le plus grand cabinet d'avocats canadien véritablement multiservices. À ce titre, il offre des conseils juridiques pratiques à des clients d'ici et d'ailleurs dans plus de domaines et de secteurs que tout autre cabinet canadien. Comptant plus de 725 avocats, agents de propriété intellectuelle et autres professionnels, BLG répond aux besoins juridiques d'entreprises et d'institutions au pays comme à l'étranger pour ce qui touche les fusions et acquisitions, les marchés financiers, les différends et le financement ou encore l'enregistrement de brevets et de marques de commerce.

blg.com

Bureaux BLG

Calgary

Centennial Place, East Tower
520 3rd Avenue S.W.
Calgary, AB, Canada
T2P 0R3

T 403.232.9500
F 403.266.1395

Ottawa

World Exchange Plaza
100 Queen Street
Ottawa, ON, Canada
K1P 1J9

T 613.237.5160
F 613.230.8842

Vancouver

1200 Waterfront Centre
200 Burrard Street
Vancouver, BC, Canada
V7X 1T2

T 604.687.5744
F 604.687.1415

Montréal

1000, rue De La Gauchetière Ouest
Suite 900
Montréal, QC, Canada
H3B 5H4

T 514.954.2555
F 514.879.9015

Toronto

Bay Adelaide Centre, East Tower
22 Adelaide Street West
Toronto, ON, Canada
M5H 4E3

T 416.367.6000
F 416.367.6749

Les présents renseignements sont de nature générale et ne sauraient constituer un avis juridique, ni un énoncé complet de la législation pertinente, ni un avis sur un quelconque sujet. Personne ne devrait agir ou s'abstenir d'agir sur la foi de ceux-ci sans procéder à un examen approfondi du droit après avoir soupesé les faits d'une situation précise. Nous vous recommandons de consulter votre conseiller juridique si vous avez des questions ou des préoccupations particulières. BLG ne garantit aucunement que la teneur de cette publication est exacte, à jour ou complète. Aucune partie de cette publication ne peut être reproduite sans l'autorisation écrite de Borden Ladner Gervais S.E.N.C.R.L., S.R.L. Si BLG vous a envoyé cette publication et que vous ne souhaitez plus la recevoir, vous pouvez demander à faire supprimer vos coordonnées de nos listes d'envoi en communiquant avec nous par courriel à desabonnement@blg.com ou en modifiant vos préférences d'abonnement dans blg.com/fr/about-us/subscribe. Si vous pensez avoir reçu le présent message par erreur, veuillez nous écrire à communications@blg.com. Pour consulter la politique de confidentialité de BLG relativement aux publications, rendez-vous sur blg.com/fr/ProtectionDesRenseignementsPersonnels.

© 2025 Borden Ladner Gervais S.E.N.C.R.L., S.R.L. Borden Ladner Gervais est une société à responsabilité limitée de l'Ontario.